These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9719204)

  • 1. Behaviour of phosphate removal with different dialysis schedules.
    Messa P; Gropuzzo M; Cleva M; Boscutti G; Mioni G; Cruciatti A; Mazzolini S; Malisan MR
    Nephrol Dial Transplant; 1998; 13 Suppl 6():43-8. PubMed ID: 9719204
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypophosphatemia in infants on continuous ambulatory peritoneal dialysis.
    Roodhooft AM; Van Hoeck KJ; Van Acker KJ
    Clin Nephrol; 1990 Sep; 34(3):131-5. PubMed ID: 2225564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regression of extraosseous calcinosis in chronic ambulatory peritoneal dialysis treatment].
    Haag B
    Z Urol Nephrol; 1989 Feb; 82(2):81-4. PubMed ID: 2728634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behaviour of beta2-microglobulin removal with different dialysis schedules.
    David S; Bottalico D; Tagliavini D; Mandolfo S; Scanziani R; Cambi V
    Nephrol Dial Transplant; 1998; 13 Suppl 6():49-54. PubMed ID: 9719205
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphate clearance in peritoneal dialysis: automated PD compared with continuous ambulatory PD.
    Sawin DA; Himmele R; Diaz-Buxo JA
    Adv Perit Dial; 2012; 28():120-5. PubMed ID: 23311227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic ambulatory peritoneal dialysis].
    Glasson P; Leski M; Favre H
    Schweiz Med Wochenschr; 1981 Aug; 111(34):1232-8. PubMed ID: 7025196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate kinetics during different dialysis modalities.
    Ratanarat R; Brendolan A; Volker G; Bonello M; Salvatori G; Andrikos E; Yavuz A; Crepaldi C; Ronco C
    Blood Purif; 2005; 23(1):83-90. PubMed ID: 15627742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. III. Treatment modalities for ESRD patients.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S51-62. PubMed ID: 10431002
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypophosphatemic effect of 1% amino acid dialysis solution.
    Arfeen S; Kirkwood A; Goodship TH; Ward MK
    Adv Perit Dial; 1989; 5():167-70. PubMed ID: 2577404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behaviour of acid-base control with different dialysis schedules.
    Feriani M
    Nephrol Dial Transplant; 1998; 13 Suppl 6():62-5. PubMed ID: 9719207
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced glycation end products in end-stage renal disease and their removal.
    Schinzel R; Münch G; Heidland A; Sebekova K
    Nephron; 2001 Apr; 87(4):295-303. PubMed ID: 11287772
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
    Mydlík M; Derzsiová K
    Kidney Int Suppl; 2001 Feb; 78():S304-7. PubMed ID: 11169031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of serum sialic acid concentration in chronic renal failure children on continuous ambulatory peritoneal dialysis and hemodialysis].
    Szprynger K; Szczepańska M; Mazur B; Dyduch A; Zwolińska D; Morawiec-Knysak A; Makulska I
    Pol Merkur Lekarski; 2000 Jul; 8(49):459-61. PubMed ID: 11070713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual renal function plays an important role in regulating parathyroid hormone in patients on continuous ambulatory peritoneal dialysis.
    Okada S; Inoue T; Nakamoto H; Ikeda N; Sugahara S; Shoda J; Okada H; Kanno Y; Suzuki H
    Adv Perit Dial; 2007; 23():150-4. PubMed ID: 17886623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of fibroblast growth factor 23 with parameters of phosphate metabolism in incident peritoneal dialysis patients.
    Golembiewska E; Safranow K; Kabat-Koperska J; Ciechanowski K; Bober J; Bogacka A
    Perit Dial Int; 2013; 33(4):447-50. PubMed ID: 23843591
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteomics in extracorporeal blood purification and peritoneal dialysis.
    Thongboonkerd V
    J Proteomics; 2010 Jan; 73(3):521-6. PubMed ID: 19527805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal phosphate removal varies by peritoneal dialysis regimen: an underestimated parameter of phosphate control.
    Botelho C; Rodrigues A; Oliveira JC; Cabrita A
    J Nephrol; 2013; 26(1):183-90. PubMed ID: 22460184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum gastrin levels and gastroduodenal lesions in children with chronic renal failure on continuous ambulatory peritoneal dialysis: a single-center experience.
    Urganci N; Ozcelik G; Kalyoncu D; Geylani Gulec S; Akinci N
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):924-8. PubMed ID: 22569084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.